PMID- 31642859
OWN - NLM
STAT- MEDLINE
DCOM- 20200507
LR  - 20200624
IS  - 2013-6463 (Electronic)
IS  - 1575-0620 (Print)
IS  - 1575-0620 (Linking)
VI  - 21
IP  - 2
DP  - 2019
TI  - Analysis of the management of antipsychotics in a group of prisons.
PG  - 88-94
LID - S1575-06202019000200088 [pii]
AB  - OBJECTIVE: To assess the use of prescribed antipsychotic treatments in the 
      Spanish prison population in order to determine whether there are differences in 
      efficacy and cost between the different long-acting antipsychotic injectables 
      (LAIs). MATERIAL AND METHOD: An observational, retrospective study was carried 
      out in twelve prisons and in two prison psychiatric hospitals. To assess 
      efficacy, all the clinical histories of patients with some kind of LAI were 
      reviewed and only those who were in a situation of therapeutic stability were 
      selected, defined as those treatments that had not undergone any change in the 
      three last months, both in doses and in the association of another antipsychotic. 
      RESULTS: Of the 11,953 inmates included in the study, 1,851 (15.5%) received 
      prescriptions for an antipsychotic, 415 in penitentiary psychiatric hospitals 
      (87%) and 1,436 in prisons (12%), which is a much higher prevalence than that 
      found in the population. Regarding the prescription pattern of LAIs, paliperidone 
      is the most widely prescribed in prison psychiatric hospitals and prisons, 
      followed by aripiprazole, zuclopenthixol and risperidone. Finally flufenazine, 
      olanzapine and paliperidone quarterly, which are scarcely represented. Of the 292 
      patients with LAI, 41% (121 patients) are with monotherapy and 59% (171 patients) 
      are with polytherapy, which is similar to the data found in the bibliography. 
      DISCUSSION: The use of prescribed LAIs amongst inmates is widespread. Polytherapy 
      is also a common phenomenon, although there is a downward trend due to the use of 
      more recently marketed drugs. Since the use of LAI is long-term, with numerous 
      side effects and a wide range of prices, it is essential to consider the 
      patient's risk factors and the cost of treatment alongside the therapeutic 
      efficacy.
FAU - Hervas, G
AU  - Hervas G
AD  - Pharmacy Unit of Albolote Prison. Granada.
FAU - Ruano, C
AU  - Ruano C
AD  - Seville Prison Psychiatric Hospital.
FAU - Sanz-Alfayate, G
AU  - Sanz-Alfayate G
AD  - La Moraleja Prison. Palencia.
FAU - Algora, I
AU  - Algora I
AD  - Madrid III Prison.
FAU - Celdran, M A
AU  - Celdran MA
AD  - Alicante Prison Psychiatric Hospital.
FAU - Mur, M A
AU  - Mur MA
AD  - Zuera Prison. Zaragoza.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - Spain
TA  - Rev Esp Sanid Penit
JT  - Revista espanola de sanidad penitenciaria
JID - 101284897
RN  - 0 (Antipsychotic Agents)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/economics/*therapeutic use
MH  - Drug Utilization/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - *Prisons
MH  - Retrospective Studies
MH  - Schizophrenia/*drug therapy
MH  - Spain
PMC - PMC6813665
EDAT- 2019/10/24 06:00
MHDA- 2020/05/08 06:00
PMCR- 2019/07/31
CRDT- 2019/10/24 06:00
PHST- 2018/08/30 00:00 [received]
PHST- 2018/11/13 00:00 [accepted]
PHST- 2019/10/24 06:00 [entrez]
PHST- 2019/10/24 06:00 [pubmed]
PHST- 2020/05/08 06:00 [medline]
PHST- 2019/07/31 00:00 [pmc-release]
AID - S1575-06202019000200088 [pii]
AID - 00004 [pii]
PST - ppublish
SO  - Rev Esp Sanid Penit. 2019;21(2):88-94.